[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605929":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":35,"centralContacts":39,"locations":45,"responsibleParty":97,"collaborators":31,"id":99,"slug":100,"hasResults":101,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":31,"eligibilityCriteria":105,"healthyVolunteers":106,"sex":107,"minAge":108,"maxAge":109,"enrollmentInfo":110,"targetDuration":31,"studyType":113,"phases":114,"briefSummary":116,"conditions":117,"keywords":31,"overallStatus":48,"whyStopped":31,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":128},{"fullName":5,"class":6},"Merck Sharp & Dohme LLC","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"V118E","EXPERIMENTAL","Participants receive intramuscular (IM) injection of V118E in a 2-dose regimen administered on Day 1 and Day 29.",[13],"Biological: V118E",{"label":15,"type":16,"description":17,"interventionNames":18},"PREVNAR 20™ + Saline","ACTIVE_COMPARATOR","Participants receive one dose of IM injection of PREVNAR 20™ in a 2-dose regimen on Day 1 followed by one dose of saline on Day 29.",[19,20],"Biological: PREVNAR 20™","Biological: Saline",[22,28,32],{"type":23,"name":9,"description":24,"armGroupLabels":25,"otherNames":26},"BIOLOGICAL","IM administration",[9],[27],"V118\u002FVA-017",{"type":23,"name":29,"description":24,"armGroupLabels":30,"otherNames":31},"PREVNAR 20™",[15],null,{"type":23,"name":33,"description":24,"armGroupLabels":34,"otherNames":31},"Saline",[15],[36],{"name":37,"affiliation":5,"role":38},"Medical Director","STUDY_DIRECTOR",[40],{"name":41,"role":42,"phone":43,"phoneExt":31,"email":44},"Toll Free Number","CONTACT","1-888-577-8839","Trialsites@msd.com",[46,64,74,87],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Velocity Clinical Research, Hallandale Beach ( Site 0003)","RECRUITING","Hallandale","Florida","33009","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-80.14838,25.9812,{"lat":58,"lon":57},[61],{"name":62,"role":42,"phone":63,"phoneExt":31,"email":31},"Study Coordinator","954-455-5757",{"facility":65,"status":66,"city":67,"state":50,"zip":68,"country":52,"countryCode":53,"cosmosGeoPoint":69,"geoPoint":73,"contacts":31},"QPS-MRA, LLC-Early Phase ( Site 0002)","ACTIVE_NOT_RECRUITING","South Miami","33143",{"type":55,"coordinates":70},[71,72],-80.29338,25.7076,{"lat":72,"lon":71},{"facility":75,"status":48,"city":76,"state":77,"zip":78,"country":52,"countryCode":53,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0004)","Springfield","Missouri","65802",{"type":55,"coordinates":80},[81,82],-93.29824,37.21533,{"lat":82,"lon":81},[85],{"name":62,"role":42,"phone":86,"phoneExt":31,"email":31},"417-893-6113",{"facility":88,"status":66,"city":89,"state":90,"zip":91,"country":52,"countryCode":53,"cosmosGeoPoint":92,"geoPoint":96,"contacts":31},"University of Texas Medical Branch ( Site 0001)","Galveston","Texas","77555-1115",{"type":55,"coordinates":93},[94,95],-94.7977,29.30135,{"lat":95,"lon":94},{"type":98,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100605929","phase-1-a-study-of-v118e-in-healthy-participants-v118e-003-100605929",false,"NCT07168915","A Study of V118E in Healthy Participants (V118E-003)","A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V118 Formulation E in Healthy Adults","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n\\- Is in good health before randomization\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has a history of invasive pneumococcal disease or known history of other culture-positive pneumococcal disease within 3 years prior to receiving study vaccination\n* Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases",true,"ALL","18 Years","49 Years",{"count":111,"type":112},126,"ESTIMATED","INTERVENTIONAL",[115],"PHASE1","Researchers are looking for new vaccines to prevent illnesses caused by a type of bacteria called Streptococcus pneumoniae. There are many different types of Streptococcus pneumoniae bacteria, called serotypes. Vaccines contain small parts of certain serotypes. These parts will not cause an infection but help the body create antibodies (proteins) to fight the bacteria.\n\nPREVNAR 20™ is a vaccine given to help to prevent disease from Streptococcus pneumoniae bacteria. Researchers designed a new vaccine, V118E, to help prevent disease from Streptococcus pneumoniae bacteria.\n\nThe goal of this study is to learn how safe V118 formulation E is in Healthy Adults and how well people tolerate it.",[118],"Healthy","2026-06-25",{"date":121,"type":122},"2026-06-29","ACTUAL",{"date":124,"type":122},"2025-10-08",{"date":126,"type":112},"2027-11-12",{"name":5,"class":6},4]